BioSpace News Archive

Avails Medical, a pioneer in rapid, automated, and fully electrical antibiotic susceptibility testing (eAST™) announced today the transition to the next phase of its CARB-X grant.

Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I.

i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF).

Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion.

Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, announced the release of the first patient advocacy outreach webinar featuring presentations by Opus leadership Ben Yerxa, Ph.D., Chief Executive Officer; Ash Jayagopal, Ph.D., Chief Scientific Officer; Joe Schachle, Chief Operating Officer; and Jennifer Hunt, Chief Development Officer.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.

AlgoTx, a biotechnology company dedicated to developing treatments for complex pain, announced today the initiation of its Phase 2 global clinical trial in Chemotherapy-Induced Peripheral Neuropathy in adult patients.

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022.

ANGLE plc, a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 30 June 2022 on Thursday 29 September 2022.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Dr. Rob Quinn as Chief Financial Officer, effective immediately.